BioSpace News Archive

Drug Development

Using Stem Cells to “Cure” Baldness

Using human induced pluripotent stem cells (iPSCs), researchers with Sanford Burnham Prebys Medical Discovery Institute in La Jolla, California, were able to grow natural-looking hair that grows through the skin.

June 28, 2019
·
2 min read
·
Mark Terry
Job Trends

Scott Gottlieb Joins Pfizer Board Weeks After Departing from FDA

Gottlieb’s knowledge of the regulatory and political landscape will be a boon for Pfizer as it dives deeper into oncology.

June 28, 2019
·
2 min read
·
Alex Keown
Deals

Karuna Therapeutic IPO to Raise $89.2 Million for Neuropsychiatric Drug Development

The company is working on developing therapies for neuropsychiatric diseases. Karuna is expecting data from a Phase II clinical trial later this year of KarXT xanomeline/trospium chloride, a muscarinic receptor modulator, to treat acute psychosis associated with schizophrenia.

June 28, 2019
·
3 min read
·
Mark Terry
Policy

Senate Committees Advance Prescription Price Lowering Bills

Four bills aimed at lowering prescription drug prices were advanced out of the U.S. Senate Judiciary Committee this week and will head to a vote on the Senate floor.

June 28, 2019
·
2 min read
·
Alex Keown
Business

Draper and Bristol-Myers Squibb Ink Toxicity Testing Deal

Draper, based in Cambridge, Massachusetts, signed a tissue model development deal with Bristol-Myers Squibb. The companies will collaborate on developing a unique liver tissue model to screen drugs for toxicity.

June 28, 2019
·
2 min read
·
Mark Terry
Drug Development

The Clinical Catch-Up for Monday, July 1

Exiting the last week of June and heading into July, a number of companies announced results from ongoing clinical trials. Here’s a look.

June 28, 2019
·
3 min read
·
Mark Terry
Drug Development

New Research Discovery - Alzheimer’s and Toxicity Pathways

Researchers discovered a pathway that helps regulate inflammation and also prevents the buildup of toxic proteins related to Alzheimer’s.

June 28, 2019
·
2 min read
·
Alex Keown